{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:50:47Z","timestamp":1790441447069,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,7,4]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>NPM1 RT-PCR levels &gt;1% are associated with poor overall and disease-free survival in AML patients treated with chemotherapy. NPM1 MRD levels &gt;10% are associated with poor overall and disease-free survival in AML patients after allogeneic transplantation.<\/jats:p>","DOI":"10.1182\/blood-2012-10-461749","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T04:34:48Z","timestamp":1368074088000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":183,"title":["The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML"],"prefix":"10.1182","volume":"122","author":[{"given":"Nona","family":"Shayegi","sequence":"first","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kramer","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schaich","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Heiderich","sequence":"additional","affiliation":[{"name":"AgenDix GmbH, Dresden, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfert","family":"Landt","sequence":"additional","affiliation":[{"name":"TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111819401287900_B1","first-page":"3074","article-title":"Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.","volume":"93","author":"Kiyoi","year":"1999","journal-title":"Blood"},{"issue":"12","key":"2019111819401287900_B2","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"issue":"3","key":"2019111819401287900_B3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111819401287900_B4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/85820","article-title":"Dominant-negative mutations of CEBPA, encoding CCAAT\/enhancer binding protein-alpha (C\/EBPalpha), in acute myeloid leukemia.","volume":"27","author":"Pabst","year":"2001","journal-title":"Nat Genet"},{"issue":"13","key":"2019111819401287900_B5","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019111819401287900_B6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111819401287900_B7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3324\/haematol.12153","article-title":"NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.","volume":"93","author":"Falini","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2019111819401287900_B8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1021\/bi00429a017","article-title":"Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth.","volume":"28","author":"Chan","year":"1989","journal-title":"Biochemistry"},{"issue":"30","key":"2019111819401287900_B9","doi-asserted-by":"crossref","first-page":"18227","DOI":"10.1016\/S0021-9258(17)44742-9","article-title":"Structure of the gene for rat nucleolar protein B23.","volume":"265","author":"Chang","year":"1990","journal-title":"J Biol Chem"},{"issue":"4","key":"2019111819401287900_B10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.11007","article-title":"Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.","volume":"92","author":"Falini","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"2019111819401287900_B11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/hon.904","article-title":"Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.","volume":"27","author":"Rau","year":"2009","journal-title":"Hematol Oncol"},{"issue":"6","key":"2019111819401287900_B12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CCO.0b013e3283313dfa","article-title":"Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.","volume":"21","author":"Falini","year":"2009","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"2019111819401287900_B13","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2005-11-4745","article-title":"Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.","volume":"107","author":"Falini","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111819401287900_B14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/leu.2008.326","article-title":"A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.","volume":"23","author":"Bolli","year":"2009","journal-title":"Leukemia"},{"key":"2019111819401287900_B15","author":"Le Arber"},{"issue":"18","key":"2019111819401287900_B16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111819401287900_B17","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","article-title":"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.","volume":"106","author":"Schnittger","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111819401287900_B18","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111819401287900_B19","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2005-04-1733","article-title":"Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.","volume":"106","author":"Suzuki","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111819401287900_B20","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1158\/0008-5472.CAN-05-4316","article-title":"Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.","volume":"66","author":"Chou","year":"2006","journal-title":"Cancer Res"},{"issue":"6","key":"2019111819401287900_B21","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111819401287900_B22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2404637","article-title":"Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations.","volume":"21","author":"Chou","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111819401287900_B23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2141.2008.07488.x","article-title":"Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.","volume":"144","author":"Papadaki","year":"2009","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111819401287900_B24","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111819401287900_B25","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111819401287900_B26","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/sj.leu.2404367","article-title":"Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping.","volume":"20","author":"Thiede","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2019111819401287900_B27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2141.1997.2933107.x","article-title":"Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation.","volume":"98","author":"Ritter","year":"1997","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111819401287900_B28","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/sim.4780122407","article-title":"Cross-validation in survival analysis.","volume":"12","author":"Verweij","year":"1993","journal-title":"Stat Med"},{"key":"2019111819401287900_B29","volume-title":"The Statistical Analysis of Failure Time Data (Wiley Series in Probability and Statistics)","author":"Kalbfleisch","year":"1980"},{"issue":"446","key":"2019111819401287900_B30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"24","key":"2019111819401287900_B31","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8476","key":"2019111819401287900_B32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement.","volume":"327","author":"Bland","year":"1986","journal-title":"Lancet"},{"issue":"3","key":"2019111819401287900_B33","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"issue":"13","key":"2019111819401287900_B34","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2009-12-258178","article-title":"Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.","volume":"116","author":"Buccisano","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111819401287900_B35","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3324\/haematol.2011.044388","article-title":"Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.","volume":"96","author":"Sockel","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"2019111819401287900_B36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/ijc.25133","article-title":"Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient.","volume":"127","author":"Swoboda","year":"2010","journal-title":"Int J Cancer"},{"issue":"2","key":"2019111819401287900_B37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.leu.2404887","article-title":"Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules.","volume":"22","author":"Liso","year":"2008","journal-title":"Leukemia"},{"key":"2019111819401287900_B38","author":"Greiner"},{"issue":"14","key":"2019111819401287900_B39","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia.","volume":"341","author":"L\u00f6wenberg","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/1\/83\/1369120\/83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/1\/83\/1369120\/83.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T15:04:29Z","timestamp":1645023869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/122\/1\/83\/31592\/The-level-of-residual-disease-based-on-mutant-NPM1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-10-461749","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,4]]}}}